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Abstract
Background: Oligonucleotide probes that are sequence identical may have different identifiers
between manufacturers and even between different versions of the same company's microarray;
and sometimes the same identifier is reused and represents a completely different oligonucleotide,
resulting in ambiguity and potentially mis-identification of the genes hybridizing to that probe.
Results: We have devised a unique, non-degenerate encoding scheme that can be used as a
universal representation to identify an oligonucleotide across manufacturers. We have named the
encoded representation 'nuID', for nucleotide universal identifier. Inspired by the fact that the raw
sequence of the oligonucleotide is the true definition of identity for a probe, the encoding algorithm
uniquely and non-degenerately transforms the sequence itself into a compact identifier (a lossless
compression). In addition, we added a redundancy check (checksum) to validate the integrity of the
identifier. These two steps, encoding plus checksum, result in an nuID, which is a unique, non-
degenerate, permanent, robust and efficient representation of the probe sequence. For commercial
applications that require the sequence identity to be confidential, we have an encryption schema
for nuID. We demonstrate the utility of nuIDs for the annotation of Illumina microarrays, and we
believe it has universal applicability as a source-independent naming convention for oligomers.
Reviewers: This article was reviewed by Itai Yanai, Rong Chen (nominated by Mark Gerstein), and
Gregory Schuler (nominated by David Lipman).
Background
Oligonucleotides (often simply referred to as oligos or oli-
gomers) are typically between 25 to 75 bases long. Micro-
array manufacturers have extensively used oligos as
sequence-specific probes to detect the expression of genes.
An oligo sequence that is located on a specific bead or
position on a microarray is usually referred to as the probe
sequence, or just as the probe. Current microarrays by
Affymetrix, Agilent, Illumina and others have tens of
thousands or even hundreds of thousands of unique
sequence probes in an array [1].
In comparison with the stable identifiers for genes that are
available through GenBank/EMBL/DDBJ, a stable naming
convention or identification scheme for probes has not
been established. As a result, some manufacturers have
internally created oligonucleotide identifiers, while others
have reused external gene identifiers for oligos. Neither of
these solutions has been ideal.
With proprietary identifiers, oligo probes that are
sequence identical may have different identifiers between
manufacturers and even between different versions of the
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same company's microarray; and sometimes the same
identifier is reused and represents a completely different
oligo, resulting in ambiguity and potentially mis-identifi-
cation of the genes hybridizing to that probe. For exam-
ple, the same probe was named as "GI_21070949-S" in
the Illumina MouseRef-8_V1 chip but as
"scl022190.1_154-S" in the later Illumina Mouse-6_V1
chip. The lack of permanency of internal identifiers causes
difficulties when combining clinical microarray data col-
lected over time using different versions of the chips.
Moreover, internally created identifiers can sometime fail
to satisfy the one-to-one mapping rule. For instance, the
same probe was identified degeneratively as both
"GI_28476905" and "scl0076846.1_142" on the Illumina
MouseRef-8_V1 chip. Thus, without a central authority to
approve the uniqueness, internally created identifiers can
fail to be globally unique, and sometimes even locally
unique. However, such a central approval process may not
be socially feasible.
Utilizing external gene identifiers apparently both solves
the cross-manufacturer data integration problem and the
permanency of the identifier. However, it blurs the dis-
tinction between oligo probes and genes. Although a
good probe sequence should uniquely hybridize with
only the RNA from a single gene, in practice this is very
difficult to achieve across a genome due to the presence of
alternative transcripts, gene families, conserved domains,
and other sequences that, if included in the probe, result
in cross hybridization with RNA species from different
genes. Moreover, the probe-to-gene mapping is dynamic
because of the continual improvement of genome anno-
tations (Figure 1). Consequently, a probe mapped to a
gene last year might map to a different gene based on the
most recent evidence in the genome database. Also, mul-
tiple distinct oligos can be used as probes for the same
gene transcript, again failing the uniqueness criterion.
Thus, the "permanent identification" of a probe by using
an external gene identifier also presents a set of limita-
tions. Figure 1 summarizes the mapping relations from
probes to genes, and from genes to annotations. Both the
gene (intron and exon structure) and functional annota-
tions to that gene may change as our knowledge of that
gene structure and function improves. Only the sequence
of the probe is stable over the time after the microarray is
manufactured. For these reasons, major commercial ven-
dors now release the exact sequence of each of their
probes, and reporting probe-level data from microarray
hybridization and analysis results in publications and
public repositories is preferred [2]. The probe-level expres-
sion data requires less inference and enables researchers to
reanalyze results with the latest mappings of probes to
annotation resources such as RefSeq [3]. Moreover, the
reporting of results at the level of the probe facilitates the
aggregation of those results across microarray platforms
[4,5]. Further, a universal naming convention based on
the sequence of the probes will enable better probe-level
studies of microarrays, especially as tiling arrays and exon
arrays are becoming popular.
Alternative approaches
A general solution to identifier-problems in biological
databases is the Life Science Identifier (LSID). LSIDs are a
concatenation of an identifier with its database context
using the syntax of urn: lsid:<author-
ity>:<lsid_namespace>: <identifier>:<version> to ensure
the global uniqueness of the identifiers [6]. For example,
the Illumina 50-mer probe "ri|E030045A12|
PX00206L14| AK053222| 1725-S" on the Mouse-6_v1
chip, is represented by the LSID as a 73-character string of
"urn:lsid:illumina.com:Mouse-6_v1:ri|E030045A12|
PX00206L14| AK053222| 1725-S". In many cases, the
resultant long string is cumbersome to use and for oligo-
nucleotides does not allow us to easily identify degenerate
names (the subset of names that are pointing to a single,
identical sequence). This identifier is very useful from the
standpoint of identifying the origin of the oligo (the ven-
dor) and the version of the microarray, and from a system
to system interoperability standpoint will preserve that
information independent of other shared header informa-
tion. However, it does not help resolve identical
sequences across vendors or between versions of the
chips. Instead of dealing with the general problem of
identifying all biological entities, we were seeking a spe-
cific solution to a simpler problem, that of finding a com-
mon identification and representation mechanism for
oligos across manufacturers.
The mapping from probes to genes and annotations Figure 1
The mapping from probes to genes and annotations. 
Note that both genes (for example the definition of a gene or 
its representative sequence) and annotations (for example, 
functional annotation by Gene Ontology) are dynamic; so are 
the mappings among them. Only the probe sequence is stable 
over time.Biology Direct 2007, 2:16 http://www.biology-direct.com/content/2/1/16
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An additional real world problem is that identifiers can be
corrupted when transmitted across platforms [7]. For
example, the tumor suppressor gene DEC1 (deleted in
esophageal cancer 1) was being automatically converted
to "1-DEC" by Microsoft Excel. Zeeberg et al. [7] offered
an Excel-specific work-around – we were seeking a more
general solution for corruption detection.
In summary, we have developed a permanent identifier
schema for oligos, one that is deterministically unique
both locally and globally. The proposed identifier should
not need a central agency to approve its uniqueness, be
easy to generate, and be resistant to transmission acci-
dents. We report such a new naming schema as nucleotide
universal identifier (nuID). We demonstrate the utility of
the nuID with the Illumina microarray systems. The same
identifier scheme can be applied to Affymetrix, Agilent
and other oligo-based microarrays. The nuID schema ena-
bles the data management system to report hybridiza-
tions, annotate microarray elements, and model the gene-
to-probe bindings explicitly at the probe-level, and we
believe it is ideally suited for labeling the identity of
microarray probes.
Results
Nucleotide Universal Identifier (nuID)
Inspired by the fact that the sequence of monomer units is
the definition of identity, we devised a simple encoding
algorithm to convert the sequence itself into a universal
identifier. Inversely, the sequence can be decoded unam-
biguously from the identifier (Figure 2). That is, the nuID
compression scheme is loss-less, ensuring a one-to-one
relationship between an nuID and a probe sequence.
In addition, we added an error detection code to the iden-
tifier. For applications where users want to keep the probe
sequence confidential, encryptions can also be easily
added to the encoding algorithm. We list a few examples
of both Affymetrix and Illumina probes in Table 1.
Error detection and identification of nuID
Although the encoding and decoding of the nuID is an
error-free process (i.e., 100% faithful conversion between
the nuID and the oligo sequence), the nuID, same as any
identifiers, can be accidentally modified during the data
transmission process. Besides typos, Zeeberg et al. [7]
demonstrated that applications, such as Excel, can acci-
dentally modify the identifiers. Although such accidents
are rare in reality, they have serious consequences when
they occur. Another real life situation is that the users
might mistakenly take another kind of identifier (a text or
string) and request an nuID conversion to an oligo
sequence. In order to solve these problems, we have
devised a build-in mechanism to make the nuID algo-
rithm "intelligent".
The error-checking concept is well known in other engi-
neering fields and is nearly ubiquitous in communica-
tions; this concept has not, to our knowledge, previously
been applied to genomic identifiers. We have chosen a
standard checksum error-checking scheme for its simplic-
ity and efficiency. In order to estimate the real error detec-
tion power of the current implementation (N = 21, see
Equation 4 in Methods), we simulated two scenarios:
mutating a number of characters in a legitimate nuID; and
randomly generating a "spoof" nuID using 95 printable
ASCII characters. Under each scenario, the simulation was
repeated for 105 times, and the estimated error detection
rate is shown in Table 2. The checksum algorithm can
detect the majority of errors in both scenarios, and the
detection power increases with the number of mutated
characters. The error detection rates of the nuID (N = 21)
are always over 97.5% in the mutation scenario. Consid-
Table 1: Examples of nuIDs
Array Type Manufacturer's Proprietary Identifier Nucleotide Sequence nuID
Affymetrix Human 206064_s_at_probe1 TGTATATGTCTGGTTTTCTTACCCC a7M7ev98VQ
Illumina Human GI_23097300-A GCTTCACTCGCTTCCCAGGGGCTCCGTTCACCAA
CTACATGAGCTACACG
cn0dn1Sqdb0UHE4nEY
Illumina Mouse TRBV23_AE000664_T_cell_receptor
_beta_variable_23_106-S
GACCCTTCGAAGTGAAAGAACACAGTCATGTTATA
TGGTATAGTCATGGT
9hX2C4CBEtO8zrMtOs
The encoding and decoding process of nuID Figure 2
The encoding and decoding process of nuID. The solid 
arrows represent the encoding process, and the dashed 
arrows represent the decoding process. The bold-italic 
number 11 is the numeric value of the checking code "L". 
The "AA" at the end of sequence is the padded nucleotides.Biology Direct 2007, 2:16 http://www.biology-direct.com/content/2/1/16
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ering that this type of mutation is rare in reality, the error
detection rates of the nuID should be sufficient for most
applications. For the second simulation scenario, the
detection rate of a random sequence is over 99.9%. This
means a legitimate nuID can almost always be differenti-
ated from a common text or sequence. If an application
has a more stringent error-checking requirement, one
more digit of checking code can be added. We have
named this identifier nuID2 (N = 1344) to distinguish it
from our standard encoding scheme. A more sophisti-
cated error detection algorithm can also be applied, and
the detection power can be further improved. However,
these techniques will add to the length of the identifier
and increase the computation required to encrypt and
decrypt the probe sequences.
Encryption capability of nuID
For some applications, users may not want the probe
sequence public. In this case, an additional encryption
step can be added to the nuID. Suppose f(x) and f-1(x) is
the encryption and decryption algorithm respectively.
Then following Equation (1) and (2), we can easily
encrypt and decrypt the nuID.
where xnuID is the base-64 number corresponding to the
nuID, and   is the encrypted base-64 number, which
can be further transformed as a Base64 encoding identi-
fier, i.e. the encrypted nuID. Different encryption algo-
rithms can be adopted for different application
requirements. We have not released code with encryption
algorithm and are providing it as a convenience for appli-
cations where it is necessary to obfuscate the identity of
the probe.
Application of nuID to Illumina microarrays
Constructing and managing identifiers on microarrays is a
challenging problem. The design of the Illumina Mouse
microarray version 1, for example, agglomerated thirteen
sequence database sources by taking identifiers from each
of those sources and appending additional tags. Illumina
expression microarrays have employed two schemes for
identifying probes: "Probe Id" and "Target Id". The "Probe
Id" is a probe-level identifier. It is a number proprietarily
assigned by Illumina Incorporated for the internal decod-
ing process of beads and may potentially change between
different versions and occasionally between different
batches of microarrays; thus, "Probe Id" is not recom-
mended for external reporting (personal communication
with Illumina Technical Support). The "Target Id" is a
gene-level identifier, either a Genbank GI number (Mouse
version 1), or a manufacturer assigned internal identifier
(version 2 or later). Note that one "Target Id" can corre-
spond to several "Probe Ids" based on the best probe-to-
gene mapping. Neither "Probe Id" nor "Target Id" can sat-
isfy the properties of the ideal nomenclature system, as
was discussed in the introduction section.
By applying the nuID system to Illumina microarrays, we
are able to achieve the following four aims.
(1) There is a one-to-one mapping between the identifier
and probe sequence. We are able to uniquely identify and
thus quantify different probes of the same gene, which
enables us to search for evidences of alternative splicing.
Moreover, the nuID makes the external reporting of
microarray results feasible at the probe level.
(2) The nuID can be directly converted to the probe
sequence, and be used to get the most updated RefSeq
matches and annotations (see the paper companion web-
site). The available sequence also enables future studies to
model the potential cross-hybridization or binding affin-
ity of the probes explicitly.
(3) The nuID identifiers are permanent and consistent.
The same probe in different versions of the microarrays
always has the same identifier.
(4) A shared annotation database of 50-mers, which is
independent of array versioning and manufacturers, was
xf x nuID nuID ’( ) = (1)
xf x nuID nuID = − 1(’ ) (2)
x nuID ’
Table 2: The error detection power of the nuID checksum algorithm (N = 21)
L 1-character 2-character 3-character Random
25mer 0.97780 0.97918 0.98689 0.99924
50mer 0.97724 0.97838 0.98607 0.99997
100mer 0.97894 0.97825 0.98617 1*
L and N are defined in Equation (3) and (4) in Methods. The column "1-character" is the error detection rate of an nuID with only one character 
mutated. Similar definition for column "2-character" and "3-character". "Random" column is error detection rate of a random ASCII string. The 
optimum detection power is 1.0.
* We realize the detection of nuIDs for 100mers is not guaranteed, but in none of our simulations did we ever encounter a randomly assembled 
string that was a valid nuID.Biology Direct 2007, 2:16 http://www.biology-direct.com/content/2/1/16
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created. The use of nuIDs will simplify and standardize
the maintenance and usage of probe annotations.
Discussion and conclusion
Similar to the manufacturer independent chemical for-
mula (for example, H2O) used to identify a chemical com-
pound, we formulated a universal identifier that
guarantees global uniqueness for oligonucleotides. Math-
ematically, the nuID encoding of the sequence is lossless
and there is a one-to-one correspondence of the probe
sequence to an nuID. A significant advantage of nuIDs is
that a sequence can be converted to an nuID by any indi-
vidual yet is guaranteed to be globally unique and inter-
operable; no central authority is necessary to assess the
uniqueness and approve the legitimacy of the identifier.
The nuID schema has three significant advantages over
using the oligo sequence directly as an identifier: first it is
more compact due to the base-64 encoding; second, it has
a built-in error detection and self-identification; and
third, it can be encrypted in cases where the sequences are
preferred not to be disclosed.
By incorporating the nuID naming scheme into the probe
annotation workflow, it is easier to build a generic anno-
tation pipeline that is independent of manufacturer and
makes the maintenance of annotations independent of
the manufacturer. More importantly, we are able to make
the probe-to-gene mapping explicit. Given the prolifera-
tion of gigabit/second interconnects and the efficiency of
modern computer architectures, the overhead cost of
using nuIDs as the primary identifier for a sequence versus
an 8 or 10 digit number is trivial. The encoding and
decoding algorithm of the nuID has been implemented in
R, Perl, and ColdFusion and can be downloaded from the
companion website listed in this article.
We have demonstrated the utility of this encoding schema
with Illumina microarrays. As shown in Table 1, it is actu-
ally more compact and efficient for the 25-mer based
Affymetrix system. The use of nuIDs will eliminate the
need to maintain the probe-to-sequence lookup table cur-
rently in the Bioconductor distribution. The nuID and
consequently the availability of the probe-sequence itself,
enables one to explicitly model individual probe behav-
iors, which can be used in probe-selection [8], alternative-
transcription modeling [9], background binding affinity
modeling [10], or probe-affinity modeling [11]. In addi-
tion to microarray probes, we have found that the nuID,
without modification, can also be used to name SAGE
[12] tags. For example, the 17-nucleotide SAGE tag of
"GCTGATATTTAAAAGAG" can be identified by the nuID
of "BnjPwCI", with the same advantages as discussed in
the paper. We also expect that nuIDs will be used to cross-
reference databases, including commercial catalogs and
inventory control systems.
The nuID scheme is simple to implement, but was not
obvious to conceive. The general concept and implemen-
tation of the nuID is also applicable to oligopeptides and
other objects that are a sequence of defined monomers.
Another further application, that has not escaped our
notice, is that the encoded string allows us to quickly and
easily identify whether the oligos are identical or
frameshifted from each other using standard bitstring
comparison routines.
Methods
Base64 encoding is a scheme that encodes binary data as
a string composed of a set of 64 characters. It is widely
used in Internet data transfer for its efficiency and ease of
use. The transformation of DNA sequence into Base64
results in a three-fold, lossless compression of the nucle-
otide sequence.
To encode a DNA oligonucleotide sequence, we use a var-
iation on standard Base64 encoding, where "+" and "/"
are replaced with "_" and "." to avoid misinterpretation by
some analytical applications, particularly with the "+".
Similar to the Base64 standard, the character set A-Z, a-z,
0–9, "_" and ".", represent the base-64 numbers of 0–63.
The following steps are used to convert a nucleotide
sequence to Base64. First, four nucleotides A, C, G and T
(U) are mapped to the base-4 numbers 0, 1, 2 and 3; then
three base-4 digits are combined as one base-64 digit;
finally, the base-64 number is mapped to the Base64-
encoded character set. This is the essence of the nuID cod-
ing scheme. Note that since "A" is mapped to 0, sequences
that are not divisible by three will appear to have been
padded with "A"s. In order to make the identifier non-
degenerate, we therefore need to add a 'length' bit, to spec-
ify whether in the original sequence the last triplet had 1,2
or 3 real nucleotides. Also, the basic encoding steps do not
incorporate self-identification or error checking, which
are also desirable attributes for a coding scheme.
By incorporating error checking directly into the nuID,
errors occurring during the transmission of the nuID can
be immediately detected. This also allows us to differenti-
ate an nuID from an arbitrary character string, providing a
means for the auto-detection of nuIDs. Furthermore,
because nucleotide "A" is padded at the end of nucleotide
sequence to make the sequence length divisible by three,
we need to record the number of padded "A"s. To fulfill
these three requirements, we added a checking code C at
the beginning of the Base-64 encoded string. The base-64
numeric value of the checking code C is:
c = 3 * n + p, p ∈ {0, 1, 2} (3)Biology Direct 2007, 2:16 http://www.biology-direct.com/content/2/1/16
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where c is the base-64 numeric value of checking code C,
p is the number of padded "A"s, n is the checksum residue
of module N, and L is the length of base-64 number di. To
maximize the power of error detection, we selected N =
21, and thus c ∈ {0,...,62}. Figure 2 shows an example of
encoding and decoding process of oligonucleotide
sequence "TGTATATGTCTGG" and its corresponding
nuID "L7M7eg". In this example, the oligonucleotide
sequence is first padded with two (p = 2) "A"s to make the
sequence length divisible by three; then every three nucle-
otides are transformed to a base-64 number; based on
Equation (4), the checksum of adding all 5 Base64 num-
bers is 192, taking the modulo 21 and getting n  = 3;
finally, based on Equation (3), multiplying n by 3, and
adding the number of padding bases p (p = 2) to get the
checking code value c (c = 11).
The decoding process is just the reverse of encoding. The
checking code is separated first and converted to a
numeric value c. Based on Equation (3), we can calculate
the checksum residue, n, and the number of padded "A"s,
p. In parallel, the checksum residue, n, can also be calcu-
lated based on Equation (4) by using the numeric values
of the encoded base-64 string. If the two estimated n
based on Equation (3) and (4) are different, an error will
be reported. It indicates the input string is not an nuID or
that there is an error in the storage or transmission of the
identifier. The algorithms above are implemented in R
and Perl programming language and also as a webservice
for broader accessibility (see the paper companion web-
site).
Availability
The encoding and decoding algorithm is implemented in
R, Perl, and ColdFusion. Supplemental data is at [13] and
also as a web server and a webservice accessible at [14].
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Reviewer's comments
Review 1
Dr. Itai Yanai, Department of Molecular and Cellular Biol-
ogy, Harvard University
In this manuscript Lin and colleagues address a problem
in microarray probe nomenclature. As microarray design
is becoming more and more commonplace, new probes
are being designed at an increasing rate. Likewise, the
annotation of the RNA species targeted by the probes is
quickly being updated. In such a situation, the authors
point out, the only stable entity
is the sequence of the probe. They propose that the probe
ID should be based upon the actual sequence, encoded in
base-64 along with a checksum to detect corruption of the
identifier.
I agree with the author's assessment of the situation in
probe nomenclature. Furthermore, I plead guilty myself in
introducing some probe identifiers that perhaps may have
been better named. However, many probe identifiers have
the usefulness of immediately communicating the target
they were from the encoded-sequence identifier. Never-
theless, the proposed system is potentially useful in the
modern era of integrating microarray data based upon the
probe sequence alone.
Perhaps one compromise would be for each lab to design
two probe identifiers per prone – one formal identifier in
the proposed format to be used during publication, and a
second identifier for internal use in the lab based upon
current annotations. The second informal identifier can
change with time while the first, of course, is fixed and
true.
Author's response
We completely agree with the reviewer's opinion. In addition to
the deterministically unique and permanent identifier of nuID
for computers, a more flexible and less stringent label can be
used to facilitate human communications.
Review 2 (nominated by Dr. Mark Gerstein)
Dr. Rong Chen, Department of Medical Informatics, Stan-
ford University
This paper addresses a very important problem, standard-
izing the probe naming in microarrays. It describes an effi-
cient encoding algorithm to transfer a probe sequence
into a universal identifier with automatic error detection.
It will greatly facilitate microarray data re-analysis and
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cross-platform comparison. I have no reservation in rec-
ommending it for publication.
Here are some suggestions to make it more readable and
helpful to the community. The equation 4 in the method
section is not very understandable. Although the authors
have provided a R function, a web server for batch encod-
ing and decoding would be more convenient.
Author's response
We followed the reviewer's suggestion and rewrite the descrip-
tion of Equation 4 by adding an example to explain it. We also
added a web service for batch conversion of nuIDs.
Review 3 (nominated by Dr. David Lipman)
Dr. Gregory Schuler, NCBI
This reviewer provided no comments for publication.
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